IMPAKT 2011 – Breast Cancer Conference
Brussels, Belgium - 05 May - 07 May 2011
The 3rd IMPAKT Breast Cancer Conference, held in Brussels from the 5th to the 7th of May 2011, gathered nearly 600 participants from 51 different countries, re-confirming itself as the leading event on translational research in breast cancer.
The Conference was introduced by the Pre-IMPAKT Training Course dedicated to early-career oncologists and continued presenting the numerous discoveries that already have, or will have impact, on breast cancer research and treatment. The best abstracts session showcased the latest scientific data, and facilitated the exchange of cutting edge information and its implementation into clinical practice.
The poster walking session led by expert faculty members was highly appreciated. Not only the session provided explanations and insights on specific abstracts, but it also enabled discussion about the results and their application into clinical practice, and proved to be an ideal setting to network with fellow colleagues.
The Conference Co-Founders, Martine Piccart and José Baselga reiterated that the objective of the IMPAKT Conference is to “find strategies to determine how the effective treatments against breast cancer that are already available can be made more and most effective by selecting specifically who should receive them based on the biological profile of their single tumour.”
- Clinically challenging subtypes
- Emerging targets - new drugs
- Pre-operative therapy
- To provide information of the myriad discoveries that already have or will have impact on breast cancer research and treatment in the near future
- To put in perspective advances on a molecular level in cell biology, molecular pathways exploited for clinical purposes, and a wide range of diagnostic, prognostic and predictive tools for breast cancer
- To keep in tune with scientific progress in breast cancer research as the therapeutic road from the laboratory to the clinic shortens
- To focus on premier data and technologies that sharp the knife of molecular dissection and define the cellular structures that determine responsiveness to novel therapies
- To promote collaboration in breast cancer research, new ideas for projects, and enables new contacts